The emerging class of GLP-1 receptor and GIP co-agonist medications, like tirzepatide, semaglutide, and the newly introduced retatrutide, represent significant advances in diabetes treatment . Although https://kpvpeptide195518.my21blog.com/940709/tirzepatide-a-thorough-look